中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 5
May  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(5): 1053-1058

Influence of artificial liver support system therapy on platelet in treatment of hepatitis B virus-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2022.05.015

  • Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510635, China

Research funding:

Natural Science Foundation of China(General Program) (82070611);

Sun Yat-Sen University Clinical Research 5010 Program (2020007)

More Information
  • Corresponding author: PENG Liang, pliang@mail.sysu.edu.cn(ORCID: 0000-0001-6184-5750)
  • Received Date: 2022-01-14
  • Accepted Date: 2022-02-15
  • Published Date: 2022-05-20
    Abstract
  •   Objective  To investigate the changing trend of platelet count (PLT) and related influencing factors in patients with hepatitis B virus-related chronic-on-acute liver failure (HBV-ACLF) after artificial liver support system (ALSS) therapy.  Methods  A total of 152 patients with HBV-ACLF who were hospitalized and treated in The Third Affiliated Hospital of Sun Yat-Sen University from January 2018 to November 2021 were included in the study, among whom 102 patients received plasma exchange (PE) and 50 patients received double plasma molecular absorption system combined with low-dose PE, and their clinical data and laboratory marker were measured. The independent samples t-test or the Mann-Whitney U test was used for the comparison of continuous data between two groups, and the chi-square test was used for the comparison of categorical data between two groups; a multivariate logistic regression analysis was used to investigate the risk factors for PLT > 50×109/L after ALSS therapy; the receiver operating characteristic (ROC) curve was used to investigate the value of baseline PLT in predicting PLT > 50×109/L after ALSS therapy.  Results  The patients were mostly middle-aged male adults; among the 152 patients, 70 (46.1%) had liver cirrhosis on admission, 114 (75.0%) received three sessions of ALSS therapy, and 88% had a baseline PLT count of > 50×109/L. There was a significant reduction in PLT from baseline to after ALSS therapy (79.5±47.7 vs 112.5±64.1, t=4.965, P < 0.001), and at 1 week after treatment, PLT increased to the baseline level (97.2±50.7 vs 112.5±64.1, t=1.787, P=0.075). As for the change in PLT from baseline to 1 week after ALSS therapy, the liver cirrhosis group had a significantly greater reduction in PLT than the non-liver cirrhosis group (U=1986.5, P=0.026), while there was no significant difference between different procedures of ALSS therapy and different sessions of treatment (3-5 sessions) (all P > 0.05). The multivariate logistic regression analysis showed that cirrhosis (odds ratio [OR]=3.097, 95% confidence interval [CI]: 1.255-7.645, P=0.014) and PLT > 50×109/L at baseline (OR=0.019, 95%CI: 0.002-0.154, P < 0.001) were independent risk factors for PLT > 50×109/L after ALSS therapy. The ROC curve analysis of baseline PLT showed that PLT > 80.5×109/L at baseline was the optimal cut-off value affecting PLT > 50×109/L after treatment, with an area under the ROC curve of 0.818.  Conclusion  The influence of ALSS therapy on PLT is temporary, but cirrhotic patients have a weaker PLT generation ability than non-cirrhotic patients. PLT > 80.5×109/L at baseline is the optimal cut-off value to reduce the risk of bleeding after ALSS therapy.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    SARIN SK, KEDARISETTY CK, ABBAS Z, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J]. Hepatol Int, 2014, 8(4): 453-471. DOI: 10.1007/s12072-014-9580-2.
    [2]
    BERNAL W, JALAN R, QUAGLIA A, et al. Acute-on-chronic liver failure[J]. Lancet, 2015, 386(10003): 1576-1587. DOI: 10.1016/S0140-6736(15)00309-8.
    [3]
    YOU S, RONG Y, ZHU B, et al. Changing etiology of liver failure in 3, 916 patients from northern China: A 10-year survey[J]. Hepatol Int, 2013, 7(2): 714-720. DOI: 10.1007/s12072-013-9424-5.
    [4]
    Liver Failure and Artificial Liver Group, Branch of Infectious Diseases, Chinese Medical Association. Guideline for non-bioartificial liver support systems in treatment of liver failure: 2016 update[J]. Chin J Clin Infect Dis, 2016, 9(2): 97-103. DOI: 10.3760/cma. j. issn. 1674-2397. 2016.02.001.

    中华医学会感染病学分会肝衰竭与人工肝学组. 非生物型人工肝治疗肝衰竭指南(2016年版)[J]. 中华临床感染病杂志, 2016, 9(2): 97-103. DOI: 10.3760/cma. j.issn. 1674-2397. 2016.02.001.
    [5]
    XU KL, LEI M, YUAN WF, et al. Effect of dual plasma molecular adsorption system in the treatment of hyperbilirubinemia in patients with liver failure[J]. Traum Crit Med, 2020, 8(2): 91-93, 96. DOI: 10.16048/j.issn.2095-5561.2020.02.08.

    许开亮, 雷鸣, 袁维方, 等. 双重血浆分子吸附系统治疗肝衰竭高胆红素患者疗效研究[J]. 创伤与急危重病医学, 2020, 8(2): 91-93, 96. DOI: 10.16048/j.issn.2095-5561.2020.02.08.
    [6]
    DONG JX, ZHANG XY, SUN YH. Changes of blood routine and electrolyte in plasma exchange for chronic severe hepatitis[J]. J Math Med, 2007, 20(1): 38. DOI: 10.3969/j.issn.1004- 4337.2007.01.017.

    董九香, 张细云, 孙友华. 血浆置换治疗慢性重型肝炎血常规及电解质的变化[J]. 数理医药学杂志, 2007, 20(1): 38. DOI: 10.3969/j.issn.1004-4337.2007.01.017.
    [7]
    NU RY, XIANG DD, WANG YM, et al. Effect of different anticoagulant on the activity of platelets during treatment of severe hepatitis with artificial liver(ALSS)[J]. Prac J Med Pharm, 2005, 22(10): 865-867. DOI: 10.3969/j.issn.1671-4008.2005.10.001.

    牛润章, 向德栋, 王宇明, 等. 肝素对接受人工肝治疗重型肝炎患者血小板的影响[J]. 实用医药杂志, 2005, 22(10): 865-867. DOI: 10.3969/j.issn.1671-4008.2005.10.001.
    [8]
    HUANG BB, NING L, LI WY, et al. Establishment of a predictive model for the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure treated with plasma exchange and double plasma molecular adsorption system alone or in combination[J]. J Clin Hepatol, 2021, 37(12): 2802-2807. DOI: 10.3969/j.issn.1001-5256.2021.12.015.

    黄贝贝, 宁玲, 李文渊, 等. 血浆置换与双重血浆分子吸附系统单用或联合使用治疗HBV相关慢加急性肝衰竭患者预后预测模型的建立与评估[J]. 临床肝胆病杂志, 2021, 37(12): 2802-2807. DOI: 10.3969/j.issn.1001-5256.2021.12.015.
    [9]
    WU T, LI J, SHAO L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67(12): 2181-2191. DOI: 10.1136/gutjnl-2017-314641.
    [10]
    WANG BQ. Interpretation of 2015 guidelines on prevention and treatment of chronic hepatitis B in Chin[J/CD]. Chin J Front Med Sci (electronic edition), 2016, 8(3): 1-4. DOI: 10.3969/j.issn.1674-7372.2016.03.001.

    王贵强. 2015年中国慢性乙型肝炎防治指南解读[J/CD]. 中国医学前沿杂志(电子版), 2016, 8(3): 1-4. DOI: 10.3969/j.issn.1674-7372.2016.03.001.
    [11]
    KAMATH PS, KIM WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD)[J]. Hepatology, 2007, 45(3): 797-805. DOI: 10.1002/hep.21563.
    [12]
    LI J, LIANG X, YOU S, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatol, 2021, 75(5): 1104-1115. DOI: 10.1016/j.jhep.2021.05.026.
    [13]
    CHEN ZL, ZHANG J, TANG G. Clinical significance of platelet parameter detection before and after artificial liver therapy in patients with severe liver disease[J]. Chin J Clin Lab Sci, 2004, 22(4): 292. DOI: 10.13602/j.cnki.jcls.2004.04.032.

    陈正林, 张杰, 唐格. 重症肝病患者人工肝治疗前后血小板参数检测的临床意义[J]. 临床检验杂志, 2004, 22(4): 292. DOI: 10.13602/j.cnki.jcls.2004.04.032.
    [14]
    XIONG ML, HE JQ, YANG LL, et al. Effect of plasma exchange with two different apertures on blood cells[J]. Chin J Gerontol, 2014, 34(13): 3573-3574. DOI: 10.3969/j.issn. 1005-9202.2014.13.029.

    熊墨龙, 何金秋, 杨玲玲, 等. 两种不同孔径分离器血浆置换后对血细胞的影响[J]. 中国老年学杂志, 2014, 34(13): 3573-3574. DOI: 10.3969/j.issn.1005-9202.2014.13.029.
    [15]
    GAO YY, ZHAO YQ, WANG SJ. Incidence of the thrombocytopenia and analysis of the causes in hospitalized patients treated with heparin preparations[J]. J China-Japan Friendship Hosp, 2010, 24(4): 198-201. DOI: 10.3969/j.issn.1001-0025.2010.04.002.

    高亚玥, 赵永强, 王书杰. 肝素制剂应用患者中血小板减少症的发病率及病因分析[J]. 中日友好医院学报, 2010, 24(4): 198-201. DOI: 10.3969/j.issn.1001-0025.2010.04.002.
    [16]
    YUAN S, QIAN Y, TAN D, et al. Therapeutic plasma exchange: A prospective randomized trial to evaluate 2 strategies in patients with liver failure[J]. Transfus Apher Sci, 2018, 57(2): 253-258. DOI: 10.1016/j.transci.2018.02.001.
    [17]
    PECK-RADOSAVLJEVIC M. Thrombocytopenia in chronic liver disease[J]. Liver Int, 2017, 37(6): 778-793. DOI: 10.1111/liv.13317.
    [18]
    van der MEIJDEN P, HEEMSKERK J. Platelet biology and functions: new concepts and clinical perspectives[J]. Nat Rev Cardiol, 2019, 16(3): 166-179. DOI: 10.1038/s41569-018-0110-0.
    [19]
    CUI L, MORAGA I, LERBS T, et al. Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors[J]. Proc Natl Acad Sci U S A, 2021, 118(2): e2017849118. DOI: 10.1073/pnas.2017849118.
    [20]
    HU DH, ZHAO K, LIU LM, et al. Study of significance of platelet consumption in patients with cirrhosis during the development of thrombocytopenia[J]. J Southeast Univ(Med Sci Edi), 2018, 37(1): 69-74. DOI: 10.3969/j.issn.1671-6264.2018.01.015.

    胡东辉, 赵康, 刘黎明, 等. 血小板消耗在肝硬化患者血小板减少症发展过程中的意义[J]. 东南大学学报(医学版), 2018, 37(1): 69-74. DOI: 10.3969/j.issn.1671-6264.2018.01.015.
    [21]
    SIMONETTO DA, SINGAL AK, GARCIA-TSAO G, et al. ACG clinical guideline: Disorders of the hepatic and mesenteric circulation[J]. Am J Gastroenterol, 2020, 115(1): 18-40. DOI: 10.14309/ajg.0000000000000486.
    [22]
    GISH RG, BROTHERS JM. Current observations in the management of hypo-and hypercoagulability in patients with acute or chronic liver failure[J]. Gastroenterol Hepatol (N Y), 2021, 17(1 Suppl 1): 23-26.
    [23]
    XU SS, WEI XH, LIN W, et al. Clinical significance of platelet count and its dynamic change in patients with acute-on-chronic liver failure[J]. J Clin Hepatol, 2018, 34(4): 810-813. DOI: 10.3969/j.issn.1001-5256.2018.04.023.

    许姗姗, 韦新焕, 林伟, 等. 慢加急性肝衰竭患者血小板计数及其动态变化的临床意义[J]. 临床肝胆病杂志, 2018, 34(4): 810-813. DOI: 10.3969/j.issn.1001-5256.2018.04.023.
    [24]
    LIANG C, TAKAHASHI K, FURUYA K, et al. Platelets stimulate liver regeneration in a rat model of partial liver transplantation[J]. Liver Transpl, 2021, 27(5): 719-734. DOI: 10.1002/lt.25962.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (528) PDF downloads(55) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return